- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00351533
A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
A Randomized, Double-blind Study of the Effect of Fish Oil (Eicosapentaenoic Acid and Docosahexanoic Acid) on Lung and Systemic Inflammation in Patients With Acute Lung Injury (ALI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acute lung injury (ALI) is common among critically ill patients and is associated with a high case fatality. Only one intervention has been shown to improve survival in a large clinical trial, and new therapies targeting the inflammatory response are needed. Nutrient interventions may provide benefit; specifically there is plausible biologic rationale for administering n-3 fatty acids (n-3 FAs) found in fish oil to patients with ALI, as n-3 FAs decrease formation of eicosanoid inflammatory mediators. However, although promising results have emerged from prior studies, fish oils have only been tested in ALI patients in a commercial enteral formula containing additional nutrients, and the control group received a high-fat enteral formula that may have been proinflammatory. Therefore, no conclusion can be drawn about the independent effect of fish oils. Furthermore, the inclusion of key pharmaconutrients in feeding formulas, instead of delivering them separately as pharmaceuticals, limits exposure to the agent, as intensive care unit (ICU) patients commonly receive less than 60% of prescribed caloric needs. Finally, specialized feeding formulas are very expensive, and it may be substantially cheaper to administer pharmaconutrients separately. We believe it is time to begin to approach nutrient trials in critically ill patients differently -- to move away from including them in feeding formulas and begin delivering them like pharmaceuticals. With appropriate scientific investigation and the use of non-nutrient placebos, this novel and innovative approach is a new paradigm of investigating nutrient delivery to critically ill patients.
This study is a phase II randomized controlled trial to determine the effects of enteral eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA), both n-3 FAs found in fish oil, versus placebo on the pulmonary and systemic environments, and on clinical outcomes, in patients with ALI. We will investigate the effect of fish oil administration on several biological markers of injury and inflammation in bronchoalveolar lavage fluid and serum, on pulmonary physiologic outcomes, and on clinical outcomes.
Comparison(s): Mechanically ventilated patients with acute lung injury randomized to receive enteral fish oil versus compared to mechanically ventilated patients with acute lung injury randomized to receive placebo.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B1W8
- St. Michael's Hospital
-
-
-
-
Idaho
-
Boise, Idaho, United States, 83706
- St. Alphonsus Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Sciences University
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- University of Vermont/Fletcher Allen Health Care
-
-
Washington
-
Seattle, Washington, United States, 98104
- Harborview Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Requiring positive-pressure mechanical ventilation
- ALI criteria: PaO2/FiO2 <300, bilateral infiltrates on chest radiograph, no left atrial hypertension
- Age > 17 years
Exclusion Criteria:
- Expected ICU length of stay <48 hours
- Unable to undergo bronchoalveolar lavage at enrollment
- Unable to obtain enteral access
- Post-cardiac arrest with suspected significant anoxic brain injury
- Expected survival < 28 days
- Pregnant
- Platelet count < 30,000, active bleeding, or international normalized ratio (INR)>3.0
- History of ventricular tachycardia or fibrillation
- Receiving recombinant human activated protein C (rh-APC) for sepsis
- Acquired immune deficiency syndrome (AIDS) with CD4 count < 200
- Metastatic cancer
- History of bone marrow, lung, liver, cardiac, kidney, or pancreas transplant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Enteral fish oil
|
Liquid fish oil 7.5cc enterally every 6 hours
|
Placebo Comparator: 2
Enteral saline
|
Liquid fish oil 7.5cc enterally every 6 hours
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in BALF Leukotriene B4
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Change in BALF Interleukin-6
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Change in BALF Monocyte Chemotactic Protein-1
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Change in BALF Neutrophil Count
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent the 2nd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Static Lung Compliance
Time Frame: Day 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group remained intubated on day 5 and had this outcome available.
|
Day 5
|
Oxygenation
Time Frame: Day 5
|
PaO2/FiO2 is the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen.
30 patients in the fish oil group and 36 patients in the enteral saline group remained intubated on day 5 and had this outcome available.
|
Day 5
|
Change in Plasma Interleukin-8
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Change in Plasma Leukotriene B4
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Change in Plasma Interleukin-6
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Change in Plasma Surfactant Protein D
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Change in Plasma vonWillebrand Factor
Time Frame: Days 1 and 5
|
30 patients in the fish oil group and 36 patients in the enteral saline group underwent 2nd blood draw on day 5. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 5
|
Worst Multiple Organ Dysfunction Score (MODS) During First 28 Days After Study Enrollment
Time Frame: Throughout hospital stay
|
Full scale name is Multiple Organ Dysfunction Score (MODS), a scale measuring degree of organ dysfunction in critically ill patients. Minimum score is 0 and maximum score is 24, with 0 indicating no organ failure and 24 indicating severe failure of multiple organs. |
Throughout hospital stay
|
Ventilator-free Days During First 28 Days After Study Enrollment
Time Frame: 28 days
|
Ventilator-free days is a common outcome measure in critical care research.
A ventilator-free day is a day that a participant is alive and not receiving mechanical ventilation during the first 28 days after s/he enrolled in the study.
|
28 days
|
ICU-free Days During First 28 Days After Study Enrollment
Time Frame: 28 days
|
ICU-free days is a common outcome measure in critical care research.
An ICU-free day is a day that a participant is alive and not in the intensive care unit (ICU) during the first 28 days after s/he enrolled in the study.
|
28 days
|
Hospital Length of Stay
Time Frame: At end of hospital admission
|
At end of hospital admission
|
|
Hospital Mortality
Time Frame: At end of hospitalization
|
At end of hospitalization
|
|
60-day Mortality
Time Frame: 60 days from day of enrollment into study
|
60 days from day of enrollment into study
|
|
Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in BALF Leukotriene B4
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in BALF Interleukin-6
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in BALF Monocyte Chemotactic Protein-1
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in BALF Neutrophil Count
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent the 3rd bronchoalveolar lavage (BAL).
Participants did not undergo BALs after baseline if they were not intubated or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in Plasma Interleukin-8
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in Plasma Leukotriene B4
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in Plasma Interleukin-6
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in Plasma Surfactant Protein D
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Change in Plasma vonWillebrand Factor
Time Frame: Days 1 and 9
|
15 patients in the fish oil group and 27 patients in the enteral saline group underwent 3rd blood draw on day 9. Participants did not undergo blood draws after baseline if they were discharged from the ICU or had expired, but clinical followup data (e.g.
mortality) were collected.
|
Days 1 and 9
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Renee D. Stapleton, MD, MSc, University of Vermont
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 28503-A
- 05-7895-A 03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, Clermont-FerrandWithdrawn
-
China-Japan Friendship HospitalNot yet recruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
-
Dr. Behcet Uz Children's HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory Failure | Pediatric Acute Respiratory Distress Syndrome (PARDS)Turkey
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Western University, CanadaEnrolling by invitationCOVID-19 Acute Respiratory Distress SyndromeCanada
-
Ain Shams UniversityCompletedCOVID-19 Acute Respiratory Distress SyndromeEgypt
-
Hospices Civils de LyonTerminatedAcute Respiratory Distress Syndrome (ARDS)France
Clinical Trials on Fish oil (eicosapentaenoic acid and docosahexanoic acid)
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedProteomics | Lipoprotein Metabolism | PCSK9United States
-
The Canadian College of Naturopathic MedicineUniversity Health Network, Toronto; North York General Hospital; Ontario Brain...TerminatedEpilepsy (Treatment Refractory)Canada
-
Vanderbilt UniversityCompleted
-
Sulaiman AlRajhi CollegesUnknown
-
Wake Forest University Health SciencesTerminatedBrain Health | Brain Function | Brain DevelopmentUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruiting
-
Ohio State UniversityNational Institute on Aging (NIA)RecruitingChronic Venous Leg UlcersUnited States
-
Penn State UniversityUnited States Department of Agriculture (USDA)CompletedInflammation | Cardiovascular DiseaseUnited States
-
University of CincinnatiCompletedSchizophrenia | Fatty Acid DeficiencyUnited States
-
Instituto Valenciano de Infertilidad, IVI VALENCIAUniversity of BarcelonaCompleted